medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2003, Number 4

<< Back Next >>

Rev Biomed 2003; 14 (4)

Biology and diagnostic methods of the hepatitis C virus

Gómez-Cordero I, Álvarez-García M

Language: Spanish
References: 90
Page: 253-268
PDF size: 95.06 Kb.


ABSTRACT

Hepatitis C has become the most common form of post-transfusional hepatitis, and is responsible for over 70% of the viral illnesses of the liver. The etiological agent is the virus C and its transmission occurs by parenteral via and contaminated blood products. The window period phase ranges from 5 to 12 weeks, antibodies appear after about 20 weeks and they can persist for a lifetime. Most people with hepatitis C do not have symptoms. The phylogenetic analysis of numerous isolations of hepatitis C virus indicates the presence of different levels of genetic variability: genotypes, subtypes, and quasispecies. It is rarely diagnosed before chronic complications appear. Laboratory diagnosis of hepatitis C virus infection became possible after genome sequencing and virus description by means of genetic engineering techniques. Assays have been developed up to the third generation and detect the antibodies of the nucleus and the antigens of the NS3 and NS5 nonstructural regions.


REFERENCES

  1. Purcell R. The hepatitis C virus: overview. Hepatology 1997; 26 (Suppl 1): 11-4.

  2. Lelbs A, Schwartz B. What's the latest on hepatitis C? Contemporary Pediatrics 1998; 15:39-46.

  3. Colina R, Mogdasy MC, Cristina J, Uriarte MR. Caracterización molecular del virus de la hepatitis C en Montevideo-Uruguay. Rev Med Uruguay 2002; 18: 76-82.

  4. MacCallun FO, Baver DJ. Homologous serum jaundice: transmission experiments with human volunteers. Lancet, 1944; 1:6222-7.

  5. Havens WP. Experiment in cross immunity between infectious hepatitis and homologous serum jaundice. Proc Soc Exp Biol Med, 1945; 59:148-53.

  6. Prince AM, Brotman B, Grady GF, Kuhns WJ, Hazzi C, Levine RW, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis B virus. Lancet,1974; ii:241-6.

  7. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989; 244:359-62.

  8. Krauledat PB, Scientific organizer. The identification of the Hepatitis C virus (HCV): Development of the first direct assay for viral Non-A, Non-B Hepatitis. Report of the Proceedings. First International Symposium Hepatitis C Virus. 1989 Sept 14-15, Rome, Italy. Ortho Diagnostic System Inc. Chirion Corporation, 1989.

  9. Cuthbert JA. Hepatitis C: Progress and Problems. Clinical Microbiology Reviews, 1994; 7(4):505-32.

  10. Purcell R. The hepatitis C virus: Overview. Hepatology 1997; 26(3), Suppl. 1:S11-S14.

  11. Padrón G, Morales J. El virus de la Hepatitis C. En: Bases moleculares para el estudio de las hepatitis virales. Elfos Scientiae: La Habana, 1998; 161-84.

  12. Picazo J, Fuertes A. Diagnóstico serológico de la hepatitis C. Protocolo de diagnóstico serológico clínico. Num 5. Innogenetics Diagnostica y Terapéutica, S.A. .

  13. Liang J, Rehermann B, Seeff L, Hoofragle J. Pathogenesis Natural History, treatment, and prevention of hepatitis C. Ann Inter Med 2000; 132:296-305.

  14. Bastie A, Pawiotsky JM, Roudot Thoraval F, Dhumeaux D. Infection par le virus de l´hepatite C epidemiologie. Pathol Biol Paris 1995; 43:674-80.

  15. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31(Suppl 1):17-24.

  16. Schiff E. Update in Hepatology. Ann J Med 1996; 132:460-6.

  17. Padrón GJ, Lemos G, Sánchez G, Arús E, Domínguez R, Chinea G, et al. Evaluación de un sistema para la detección de anticuerpos contra un antígeno sintético del core del virus de Hepatitis C y su prevalencia en donantes de sangre. Biotecnología Aplicada 1994; 11(2):165-70.

  18. Rubio M, Rubio C, Nogués A, Manonelles A. Genotipos del virus de la hepatitis C. Estudio de 302 pacientes coinfectados por el virus de la inmunodeficiencia humana. Medicina Clínica 2001; 116: 650-1.

  19. Rodríguez C. Actualización sobre hepatitis viral: etiología, patogenia, diagnóstico microbiológico y prevención. Rev Cubana Med Gen Integr, 2000, 16:574-85.

  20. Koziel M. Immunology of viral hepatitis. Am J Med 1996; 100:98-109.

  21. Farci P, Orgiana G, Purcell RH. Immunity elicited by Hepatitis C virus. Clin Exp Rheumatol 1995; 13 (Suppl 13):S9-S12.

  22. Takada A, Tsutsumi M, Okanoue T, Matsushima T, Komatsu M, Fujiyama S. Distribution of the different subtypes of hepatitis C virus in Japan and the effects of interferon: a nationwide survay. J Gastroenterol Hepatol 1996; 11: 201-7.

  23. Rosa C, Osborne SJ, Griva S, Garetto F, Bonelli F, inventors; Sorin Biomedica Italia, assignee. HCV peptides and uses thereof. European Patent No. 0624597 A1. 1994; May/2.

  24. Leahy D, Todd JA, Jolley ME, inventors; Baxter diagnostics Inc., assignee. Immunoassay for non-A non-B Hepatitis. International Publication Patent No. WO 92/22571. 1992b; Dec/23.

  25. Miyakawa Y, Okamoto H, Mayumi M. Classifying Hepatitis C virus genotypes. Molecular Medicine Today (Reviews). 1995; 20-5.

  26. Esteban JI. Diagnóstico y epidemiología molecular de la infección por HCV. Documentación extraída de la 1ª Reunión de Consenso: Manejo de las hepatitis crónicas víricas en pacientes con VIH, Organizada por la Fundación FIT en Madrid el día 6 de Octubre de 2000. En:Formación e información sobre tratamientos en el VIH/SIDA, Octubre 2000 .

  27. Lunel F, Pawlotsky JM. Virus de l'hepatite C: diagnostic virologique. Pathol Biol Paris, 1995; 43(8): 681-90.

  28. Yatsuhashi H, Inove O, Koga M, Nagataki S, Mizuno K, Kolberg J, et al. Comparison of hepatitis C virus markers in patients with NANB hepatitis. J Virol Meth, 1992; 37:13-22.

  29. Habets JA, Boender J, inventors; Akzo Nobel N.V., assignee. Hepatitis C virus (HCV) non-structural-3 peptides, antibodies thereto and methods for the detection of HCV. International Publication Patent No. WO 94/13699. 1994; Jun/23.

  30. Dusheinko G, Simmonde P. Sequence variability of Hepatitis C virus and the clinical relevance. J Viral Hepat 1994; 1:3-15.

  31. Molinari JA. Hepatitis C virus infection. Dent Clin N A 1996; 40: 309-25.

  32. Neddermann P, Tomei L, Steinkuhler C, Gallinari P, Tramontano A, DeFrancesco R. The nonstructural proteins of the hepatitis C virus: Structure and functions. Biol Chem 1997; 378: 469-76.

  33. Jin L, Peterson DL. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 1995; 323:47-53.

  34. Simmonds P, Yap L, Pike IA, inventors; Murex diagnostics LTD, assignee. Common Services Agency. Hepatitis C virus type 4, 5 and 6. European Patent No. WO 9425602 A1 941110. 1994; Nov/11.

  35. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Structural Biol 1997; 4:463-7.

  36. Robinson JW, Rosas M, Guzmán F, Patarroyo ME, Moreno A. Comparison of prevalence of anti-hepatitis C virus antibodies in differing South American populations. J Med Virol 1996; 50:188-92.

  37. Ray R, Khanna A, Lagging LM, Meyer K, Choo QL, Ralston R, et al. Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. J Virol 1994; 68:4420-6.

  38. Zhang ZX, Sonnerborg A, Sallberg M. Antigenic structure of the hepatitis C virus envelope 2 protein. Clin Exp Immunol, 1994; 98:382-87.

  39. Weiner AJ, Houghton M, inventors; Chirion Corporation, assignee. Conserved motif of hepatitis C virus E2/NS1 region. Patent No. WO 9426306 A1 941124. 1994; Nov/11.

  40. Zhang ZX, Chen M, Sonnerborg A, Sallberg M. Antigenic structure of the complete nonstructural (NS2) 2 and 5 proteins of Hepatitis C virus (HCV): anti - HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. Clin Diagn Lab Immunol, 1994; 1(3):290-4.

  41. Kanai A, Tanabe K, Kohara M. Poly(U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase. FEBS Lett. 1995; 376(3):221-4.

  42. Hong Z, Ferrari E, Wright J, Chase R, Risano C, Seelig G, et al. Enzymatic characterization of hepatitis C virus NS3A-4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol 1996; 70:4261-8.

  43. Hang J, Choe J, inventors; Chiron Corporation, assignee. HCV NS3 protein fragments having helicase activity and improved solubility. US/US Patent No. WO 9712043 A2 970403. 1997; April/3.

  44. Ishido S, Fujita T, Hotta H Complex formation of NS5B with NS3 and NS4A proteins of Hepatitis C virus. Biochem Biophys Res Commun 1998; 244: 35-40.

  45. Gwack Y, Kim DW, Han JH, Choe J. Characterization of RNA binding activity and RNA helicase activity of hepatitis C virus NS3 protein. Biochem Biophys Res Commun 1996; 225:654-9.

  46. Borowski P, Heiland M, Oehlmann K, Becker B, Kornetzky L, Feucht H, et al. Non-structural protein 3 of hepatitis C virus inhibits phosphorylation mediated by cAMPdependent protein kinase. Eur J Biochem 1996; 237: 611-8.

  47. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, et al. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol 1993; 31:1493-503.

  48. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNAdependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997; 71:8416-28.

  49. Rice C III, Kolykhalov AA, inventors; Washington University, assignee. Novel 3´terminal sequence of hepatitis C virus genome and diagnostic and therapeutic uses thereof. Patent No. WO 9708310 A1 970306. 1997; Jun/3.

  50. Tanaka T, Kato N, Cho MJ, Shimotohno K. A novel sequence found at the 3' terminus of the Hepatitis C virus genome. Biochem Biophys Res Commun 1995; 215:744-9.

  51. Kolykhalov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3´terminus of hepatitis C virus genome RNA. J Virol 1996; 70:3363-71.

  52. Tanaka T, Kato N, Cho MJ, Sugiyama K, Shimotohno K. Structure of the 3' terminus of the hepatitis C virus genome. J Virol 1996; 70: 3307-12.

  53. Shukla DD, Hoyne PA, Ward CW. Evaluation of complete genome sequences and sequences of individual gene products for the classification of hepatitis C viruses. Arch Virol 1995; 140:1747-61.

  54. Mondelli MU, Cerino A, Bono F, Cividini A, Maccabruni A, Arico M, et al. Hepatitis C virus (HCV) core serotypes in chronic HCV infection. Clin Microbiol 1994; 32:2523-7.

  55. Zeuzem S, Ruster B, Lee JH, Stripf T, Roth WK. Evaluation of a reverse hybridization assay for genotyping of hepatitis C virus. J Hepatol 1995; 23: 654-61.

  56. Matsubara T, Sumazaki R, Shin K, Nagai Y, Takita H. Genotyping of hepatitis C virus: coinfection by multiple genotypes detected in children with chronic posttransfusion hepatitis C. J Pediatr Gastroenterol Nutr 1996; 22: 79-84.

  57. Lee DS, Sung YC, Whang YS. Distribution of HCV genotypes among blood donors, patients with chronic liver disease, hepatocellular carcinoma, and patients on maintenance hemodialysis in Korea. J Med Virol 1996; 49: 55-60.

  58. Takada A, Tsutsumi M, Zhang SC, Okanoue T, Matsushima T, Fujiyama S, et al. Relationship between hepatocellular carcinoma and subtypes of hepatitis C virus: a nationwide analysis. J Gastroenterol Hepatol 1996; 11: 166-9.

  59. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994; 91:8239-43.

  60. Schreier E, Roggendorf M, Driesel G, Hohne M, Viazov S. Genotypes of hepatitis C virus isolates from different parts of the world. Arch Virol (Suppl) 1996; 11:185-93.

  61. Maertens G, Stuyver L, inventors; Innogenetics N.V., assignee. New sequences of hepatitis C virus genotypes and their uses as prophylactic, therapeutic, and diagnostics agents. Patent No. WO 9613590 A2 960509. 1996: May/9.

  62. Yoshihara N. ELISA for diagnosis of infections by viruses. Nippon Rinsho 1995; 53: 2277-82.

  63. Mishiro S, Hoshi Y, Takeda K. Non-A, non-B hepatitis specific antibodies directed at host-derived epitope. Implication for an autoimmune process. Lancet 1990; 336:1400-3.

  64. Soffredini R, Rumi M, Lampertico, Aroidi A, Tarantino A, Ponticelli C, Colombo M. Increased detection of antibody to hepatitis C virus renal transplant patients by thirdgeneration assays. Am J Kidney Dis 1996; 28:437-40.

  65. Rosa C, Caborne S, Garetto F, Griva S, Rivella A, Calabresi G, et al. Epitope mapping of the NS4 and NS5 gene products of hepatitis C virus and the use of a chimeric NS4-NS5 synthetic peptide for serodiagnosis. J Virol Methods 1995; 55:219-32.

  66. Gretch DR. Diagnostic test for hepatitis C. Hepatology, 1997; 263 (Suppl) 43S-47S.

  67. Donegan E, Wright TL, Roberts J, Ascher NL, Lake JR, Neuwald P, et al. Detection of hepatitis C after liver transplantation. Four serologic tests compared. Am J Clin Pathol 1995; 104: 673-9.

  68. Farma E, Boeri E, Morsica G, McDermott J, Soldini L, Repetto CM, et al. “Single step” PCR with a sensitivity similar to nested PCR for the detection of hepatitis C virus RNA. Clin Exp Rheumatol 1995; 13 (Suppl): S59-61.

  69. Dixit V, Quan S, Martin P, Larson D, Brezina M, Dinelio R, et al. Evaluation of a novel serotyping system for hepatitis C virus: strong correlation with standard genotyping methodologies. J Clin Microbiol 1995; 33:2978-83.

  70. Tisminetzky S, Gerotto M, Pontisso P, Chemello L, Prescott LE, Rose KA, et al. Comparison of genotyping and serotyping methods for the identification of hepatitis C virus types. J Virol Meth 1995; 55:303-7.

  71. Enzymun-Test® Anti-HCV (No. 15557327). Boehringer Mannheim Immunodiagnostics 1994; ES 700/ES 607/ES 600/ES 300.

  72. MONOLISA anti-HCV Detection kit for antibodies to HCV (Hepatitis C virus or related variants) in human serum by enzyme immunoassay. Sanofi Diagnostics Pasteur, S.A. 1996; code: 806719, 03/96.

  73. Hepatitis C virus. UBI HCV EIA 4.0. Beijing United Biomedical Co., Ltd., Beijing, PR China. U.S. patent No. 5106726, Australia patent No. 635124. 81964. 1994; Jun/20.

  74. Kashiwakuma T, Hasegawa A, Kajita T, Takata A, Mori H, Ohta Y, et al. Detection of Hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J Immunol Meth 1996; 28, 190(1): 79-89.

  75. Tanaka T, Lau JY, Mizokami M, Orito E, Tanaka E, Kiyosawa K, et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol. 1995; 23: 742-5.

  76. Orito E, Mizokami M, Tanaka T, Lau JYN, Suzuki K, Yamauchi M, et al. Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes. Gut 1996; 39:876-80.

  77. Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H, et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1996; 23:1330-3.

  78. Ornopia GL, Kuramoto K. Detection of anti-hepatitis C virus using chemiluminescence. J Viral Hepat 1995; 2:215-9.

  79. AxSYm HCV®. Antígenos codificados del virus de la hepatitis C. Abbott System. 1995.

  80. ABBOTT HCV EIA 3.0. Hepatitis C virus encoded antigen (Recombinant c100-3, HC-34, HC-43, NS5). Enzyme immunoassay for the qualitative detection of antibody to hepatitis C virus (Anti-HCV) in human serum or plasma. ABBOTT Diagnostics Division, Germany, 1995.

  81. Al Meshari K, Alfurayh O, Al Ahdal M, Qunibi W, Kessie G, De Vol E. Hepatitis C virus infection in hemodialysis patients: comparison of two new hepatitis C antibody assays with a second-generation assay. J Am Soc Nephrol 1995; 6:1439-44.

  82. Boston Biomedica, Inc. Anti-HCV Low titer performance panel (PVH103) and Anti-HCV Mixed titer performance panel (PVH204). W. Bridgewater, 1995.

  83. Murex anti-HCV (Version III). Enzyme immunoassay for the detection of antibodies to hepatitis C virus (HCV). VK47/48, Bronidox ®, Henkel Chemical Co., 1994.

  84. UMELISA HCV. Para la detección de anticuerpos al virus de la hepatitis C en suero humano, plasma o sangre seca sobre papel de filtro. Centro de Inmunoensayo, Cuba, 2001.

  85. UMELOSA HCV Cualitativo. Centro de Inmunoensayo, Cuba, 2002.

  86. Bernstein D. Diagnosis and management of hepatitis C. Gastroenterology Clin Mgmt [Serial on line] 2001 Feb [Cited 2002 Feb 2]: 1(1): [28 screens] available from: url: http://www.medscape.com/MedScape/gcstro/Clinicalmgmt/CM.v01/public/index-CM.v01.html.

  87. Nasti G, Di Genaro G, Tavio M, Cadorn L, Tedeschi R, Talamini, et al. Cronic hepatitis C in HIV infection: fecsibility and sustained efficacy of therapy with interferon alfa-2b and rivabirin. AIDS 2001; 15:1783-7.

  88. Córdoba J, Olaso V, Molina JM, López B, Argüello L, Ortiz V, et al. Análisis comparativo de la carga viral mediante bDNA HCV RNA-2.0 y Amplicor HCV Monitor, en pacientes infectados por el virus de la hepatitis C. Enf Infec Microbiol 2000; 18: 6-11.

  89. Leahy D, Kink J, Byrne R, Shah D, Preisel B, Laska S, et al. Improved serologic detection of hepatitis C virus with a paramagnetic microparticle assay using multiple antigenic sequences. Transfusion 1992; 32:548-53.

  90. Todd J, Kink J, Leahy D, Preisel Simmons B, Laska S, Wolff P, et al. A novel semi-automated paramagnetic microparticle based enzyme immunoassay for hepatitis C virus: Its application to serologic testing. J Immunoassay 1992; 13:393-410.




2020     |     www.medigraphic.com